<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04741009</url>
  </required_header>
  <id_info>
    <org_study_id>CAM5776</org_study_id>
    <nct_id>NCT04741009</nct_id>
  </id_info>
  <brief_title>Perimodiolar Implant Performance in Adults With Low-Frequency Residual Hearing</brief_title>
  <official_title>A Pre-market, Open-label Feasibility, Prospective, Single-arm Multicenter Feasibility Investigation of Hearing Performance Using the CI632 in Adults With Low-frequency Residual Hearing.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cochlear</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cochlear</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the feasibility study is to investigate hearing performance (audiometry and&#xD;
      speech perception) using the CI632 in a group of adults (n=15) with low-frequency residual&#xD;
      hearing who meet inclusion criteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize hearing performance of the CI632 in an adult population under expanded indications for use.</measure>
    <time_frame>14 months</time_frame>
    <description>To characterize hearing performance of the CI632 using CNC word recognition in quiet scores with percentage correct words.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Sensorineural Hearing Loss</condition>
  <condition>Low-Frequency Residual Hearing</condition>
  <arm_group>
    <arm_group_label>CI632 Slim Modiolar Electrode</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CI632 Slim Modiolar Electrode</intervention_name>
    <description>Cochlear Ltd CI632 cochlear implant with Slim Modiolar Electrode</description>
    <arm_group_label>CI632 Slim Modiolar Electrode</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years-of-age or older at the time of surgery.&#xD;
&#xD;
          2. Low-frequency threshold at 500 Hz ≤ 50 dB HL and high-frequency pure-tone average&#xD;
             (PTA), 2000-8000 Hz ≥ 65 dB HL in the ear to be implanted.&#xD;
&#xD;
          3. Pure-tone average (PTA) (0.5k, 1k, 2k Hz) &gt; 30 dB HL in the contralateral ear.&#xD;
&#xD;
          4. CNC word recognition scores (mean of two lists) ≤ 60% in the ear to be implanted and ≤&#xD;
             80% in the contralateral ear.&#xD;
&#xD;
          5. English spoken as a primary language.&#xD;
&#xD;
          6. Willing and able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Individuals older than 70 years at the time of surgery.&#xD;
&#xD;
          2. Duration of severe to profound sensorineural hearing loss &gt; 20 years per self-report.&#xD;
&#xD;
          3. Onset of sensorineural hearing loss, for the purpose of this study, prior to 5&#xD;
             years-of-age.&#xD;
&#xD;
          4. Ossification or any other cochlear anomaly that might prevent complete insertion of&#xD;
             the electrode array.&#xD;
&#xD;
          5. Conductive overlay of 15 dB or greater at two or more frequencies, in the range of 250&#xD;
             through 1000 Hz in the ear to be implanted.&#xD;
&#xD;
          6. Hearing loss of neural or central origin.&#xD;
&#xD;
          7. Diagnosis of Auditory Neuropathy.&#xD;
&#xD;
          8. Active middle-ear infection.&#xD;
&#xD;
          9. Medical or psychological conditions that contraindicate undergoing surgery as&#xD;
             determined by the Investigator.&#xD;
&#xD;
         10. Unrealistic expectations on the part of the subject, regarding the possible benefits,&#xD;
             risks, and limitations that are inherent to the device and/or procedure, as determined&#xD;
             by the Investigator.&#xD;
&#xD;
         11. Additional handicaps that would prevent or restrict participation in the audiological&#xD;
             evaluations as determined by the Investigator.&#xD;
&#xD;
         12. Unable or unwilling to comply with the requirements of the clinical investigation as&#xD;
             determined by the Investigator.&#xD;
&#xD;
         13. Investigator site personnel directly affiliated with this study and/or their immediate&#xD;
             family (spouse, parent, child, or sibling).&#xD;
&#xD;
         14. Cochlear employees or employees of a Contract Research Organization (CRO) or&#xD;
             contractors engaged by Cochlear for the purposes of this investigation.&#xD;
&#xD;
         15. Currently participating, or has participated in the last 30 days, in another&#xD;
             interventional clinical investigation/trial involving an investigational drug or&#xD;
             device.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laura Chenier</last_name>
    <phone>422-325-4171</phone>
    <email>lchenier@cochlear.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Laura Chenier</last_name>
      <phone>442-325-4171</phone>
      <email>lchenier@cochlear.com</email>
    </contact>
    <investigator>
      <last_name>Aaron Remenschneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Laura Chenier</last_name>
      <phone>442-325-4171</phone>
      <email>lchenier@cochlear.com</email>
    </contact>
    <investigator>
      <last_name>David Friedmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Laura Chenier</last_name>
      <phone>442-325-4171</phone>
      <email>lchenier@cochlear.com</email>
    </contact>
    <investigator>
      <last_name>Erika Woodson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Laura Chenier</last_name>
      <phone>442-325-4171</phone>
      <email>lchenier@cochlear.com</email>
    </contact>
    <investigator>
      <last_name>Gail Murray, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

